MRNA Moderna Inc.

21.12
-0.35  -2%
Previous Close 21.47
Open 21.6
Price To Book 5.62
Market Cap 7,038,242,429
Shares 333,250,115
Volume 2,930,387
Short Ratio
Av. Daily Volume 2,188,621
Stock charts supplied by TradingView

NewsSee all news

  1. Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

    Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna's mRNA vaccine technology Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA

  2. Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

    mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be

  3. Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

    New interim analysis after third and final vaccination shows continued boosting of neutralizing antibody titers in both seronegative participants (exceeding seropositive baseline levels 10-fold at 90 and 180 µg) and

  4. Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that CEO

  5. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 completed.
VEGF-A(AZD8601)
Myocardial ischemia
Phase 1 completed.
mRNA-2416
Solid tumors, lymphoma
Phase 2 trial has been initiated.
mRNA-4157 (KEYNOTE-942)
Personalized cancer vaccine
Phase 1 completed.
mRNA-1388
Chikungunya vaccine
Phase 1 completed.
mRNA-1851
Influenza vaccine
Phase 1 completed.
mRNA-1440
Influenza vaccine
Phase 1 trial presented at IDWeek October 5.
mRNA-1653
Human Metapneumovirus and Human Parainfluenza Infection (hMPV+PIV3 vaccine)
Phase 2 interim data due 2H 2020.
mRNA-1647
CMV vaccine (Cytomegalovirus Infection)
Development has been paused - May 8, 2019.
mRNA-1777
RSV vaccine
Phase 1/2 trial is recruiting.
mRNA-3704
Methylmalonic Acidemia (MMA)
Phase 1 dosing has commenced - noted January 8, 2019.
mRNA-2752
Solid tumors, lymphoma
Phase 1 data released September 12, 2019 noted no significant adverse events were observed at the low and middle doses; infusion-related adverse events were observed at the high dose.
mRNA-1944
Chikungunya Virus Infection
Phase 1 data presented at ASCO June 1, 2019.
mRNA-4650
Autologous Cancer
Phase 1 dosing has commenced - August 7, 2019.
mRNA-1172
RSV vaccine
Phase 1 dosing has commenced - August 7, 2019.
mRNA-5671
KRAS cancer vaccine

Latest News

  1. Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

    Collaboration includes the National Institutes of Health (NIH) and leverages flexibility of Moderna's mRNA vaccine technology Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA

  2. Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

    mRNA-6231 encodes a long-acting selective IL-2 to preferentially expand regulatory T cells that suppress immune activity in autoimmune diseases mRNA-6981 encodes PD-L1 to treat autoimmune disease, initially to be

  3. Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

    New interim analysis after third and final vaccination shows continued boosting of neutralizing antibody titers in both seronegative participants (exceeding seropositive baseline levels 10-fold at 90 and 180 µg) and

  4. Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that CEO

  5. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  6. Moderna Announces Key 2020 Investor and Analyst Events

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key

  7. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  8. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  9. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  10. Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  11. Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results

    Positive interim results announced from Phase 1 CMV vaccine (mRNA-1647) study Positive interim results announced from Phase 1 mRNA encoding chikungunya antibody (mRNA-1944) study First participant dosed in Phase 1b

  12. Moderna to Present at Credit Suisse 28th Annual Healthcare Conference

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  13. Moderna Named Top Employer by Science for Fifth Consecutive Year

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced it has

  14. Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)

    mRNA-3927 is Moderna's second rare disease program to receive Fast Track designation mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) and mRNA-3704 (methylmalonic

  15. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  16. Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019

    hMPV+PIV3: Phase 1 data show first combination vaccine against respiratory viruses hMPV and PIV3 (mRNA-1653) boosted hMPV and PIV3 neutralizing antibody titers above baseline through seven months; safety analysis at two

  17. Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)

    mRNA-3927 is Moderna's second rare disease program with an open IND mRNA-3927 uses the same proprietary LNP formulation as mRNA-1944 (antibody against Chikungunya virus) Moderna, Inc., (NASDAQ:MRNA) a clinical stage

  18. Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University

    Collaboration seeks to explore fundamental immunological processes and identify potential therapeutic opportunities Moderna, Inc., (NASDAQ:MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA)

  19. Moderna to Present at Upcoming Investor Conferences

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its

  20. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  21. Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)

    mRNA-1944 successfully encoded for functional antibody (CHKV-24) in humans at all dose levels tested (0.1, 0.3 and 0.6 mg/kg) Antibody level predicted to protect against chikungunya infection achieved within hours;

  22. Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

    Vaccination immunized seronegative participants to levels consistent with or above seropositive titers and boosted baseline titers in seropositive participants Vaccine was generally well-tolerated Phase 2 study to

  23. Moderna Appoints Tracey Franklin as Chief Human Resources Officer

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that

  24. Moderna to Host R&D Day on September 12, 2019

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it

  25. Moderna to Present at Upcoming Investor Conferences

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its